Current and future management of Alzheimer's disease

Alzheimer's and Dementia

Volumn 4, Issue 1 SUPPL. 1, 2008, Pages

  Gauthier, Serge ^a   Poirier, Judes ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Stages; Treatment

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANXIOLYTIC AGENT; APOLIPOPROTEIN E4; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; ESTROGEN DERIVATIVE; MEMANTINE; NEUROLEPTIC AGENT; PLACEBO;

ALZHEIMER DISEASE; ANXIETY; ARTICLE; BEHAVIOR DISORDER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COHORT ANALYSIS; DEMENTIA; DEPRESSION; DISEASE SEVERITY; GLUCOSE METABOLISM; HUMAN; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RISK FACTOR; SYMPTOM;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; RISK FACTORS;

EID: 38049029661     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2007.11.010     Document Type: Article

References (11)

1. Folstein M.F., Folstein S.E., and McHugh P.R. Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 12 (1975) 189-198
2. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6 (2007) 734-746
3. Gauthier S., Reisberg B., Zaudig M., Petersen R.C., Ritchie K., Broich K., et al. Mild cognitive impairment. Lancet 367 (2006) 1262-1270
4. Kivipelto M., Ngandu T., Laatikainen T., Winblad B., Soininen H., and Tuomilehto J. Risk score for the prediction of fementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 5 (2006) 735-741
5. Feldman H.H., Gauthier S., Chertkow H., Conn D.K., Freedman M., MacKnight C., et al. Canadian guidelines for the development of antidementia therapies: a conceptual summary. Can J Neurol Sci 33 (2006) 6-26
6. Khachaturian Z.S. A chapter in the development of Alzheimer's disease research: a case study of public policies on the development and funding of research programs. Alzheimer's & Dementia 3 (2007) 243-258
7. Forette F., Seux M.L., and Staessen J.A. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352 (1998) 1347-1351
8. Teng E., Lu P.H., and Cummings J.L. Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease. Dement Geriatr Cogn Disord 24 (2007) 253-259
9. Schwam E.M., Abu-Shakra S., del Valle M., Townsend R.J., Carrillo M.C., and Fillit H. Health economics and the value of therapy in Alzheimer's disease. Alzheimer's & Dementia 3 (2007) 143-151
10. Herrmann N., Gauthier S., and Lysy P.G. Clinical practice guidelines for severe Alzheimer's disease. Alzheimer's & Dementia 3 (2007) 385-397
11. Reisberg B., Ferris S.H., de Leon M.J., and Crook T. The Global Deterioration Scale (GDS) for assessment of primary degenerative dementia. Am J Psychiatry 139 (1982) 1136-1139